-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WvWNxXxSrfX0FD6QA3tNp/GgKKw/K9Hpa7uiV1KNbf7l3Aa+H8KzJNdDmENOCC1L rD7+F6M6bKmIYhiCMNSjtw== 0001257957-08-000040.txt : 20080819 0001257957-08-000040.hdr.sgml : 20080819 20080819090853 ACCESSION NUMBER: 0001257957-08-000040 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080815 FILED AS OF DATE: 20080819 DATE AS OF CHANGE: 20080819 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVI BIOPHARMA INC CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: OR FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE SW COLUMBIA STREET 2: STE 1105 CITY: PORTLAND STATE: OR ZIP: 97258 BUSINESS PHONE: 5032270554 MAIL ADDRESS: STREET 1: ONE SW COLUMBIA STREET 2: SUITE 1105 CITY: PORTLAND STATE: OR ZIP: 97258 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Price Ben Gil CENTRAL INDEX KEY: 0001417915 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 081026434 BUSINESS ADDRESS: BUSINESS PHONE: 240-426-4695 MAIL ADDRESS: STREET 1: 801 INSPIRATION LANE CITY: GAITHERSBURG STATE: MD ZIP: 20878 4 1 edgardoc.xml PRIMARY DOCUMENT X0303 4 2008-08-15 0 0000873303 AVI BIOPHARMA INC AVII 0001417915 Price Ben Gil ONE SW COLUMBIA, SUITE 1105 PORTLAND OR 97258 1 0 0 0 Common Stock 2008-08-15 4 P 0 6582 1.22 A 31582 D Non-Qualified Stock Option (right to buy) 1.55 2008-06-20 2018-05-20 Common Stock 20000 20000 D Non-Qualified Stock Option (right to buy) 2.83 2007-10-29 2017-10-29 Common Stock 33000 33000 D Option Grant vests monthly until all shares are vested one year from date of grant. Vesting: 25% of the shares vest each year from the date of grant with all shares vesting in four years. By: Mark M Weber, Attorney-in-fact For: Ben Gill Price, MD 2008-08-18 -----END PRIVACY-ENHANCED MESSAGE-----